Articles tagged with Breast Cancer
A multicenter study found that scalp cooling reduced hair loss in certain breast cancer patients undergoing non-anthracycline adjuvant chemotherapy. The study, published in JAMA, showed that 67% of patients retained half or more of their hair after treatment.
A new study has found that radiotherapy for invasive breast cancer increases the risk of developing second primary lung cancer. The research, conducted in Taiwan, involved analyzing data from over 986,000 patients with breast cancer between 2000 and 2010. The results showed a significant increase in lung cancer incidence among women wh...
A retrospective analysis of 1,424 patients found that those with an intermediate risk recurrence score (RS) had similar outcomes whether they received chemotherapy or not. The study suggests that less is more for women with early-stage disease, potentially leading to a shift away from aggressive treatment protocols.
Researchers at the University of Illinois have developed a new tumor-targeting system that harnesses cancer cells' metabolism to deliver targeted treatments. The system, led by Jianjun Cheng, uses small-molecule sugars called azides to mark cancer cells and deliver therapeutic agents.
Scientists at Scripps Research Institute have been awarded $3.3 million to create a new class of anti-cancer drugs called antibody-drug conjugates (ADCs). These ADCs target aggressive breast cancer types with high efficiency.
Two studies found that scalp cooling devices can significantly reduce hair loss in women with breast cancer undergoing chemotherapy. In one study, patients who received scalp cooling had an average of 51% hair preservation compared to 0% in the control group. The other study also showed promising results, with 67% of patients experienc...
Researchers analyzed genetic data of 173 patients and identified CSDE1 and fusion genes in MAML3 as drivers of the disease, providing opportunities for molecular diagnosis and prognosis. The study also found four distinct subtypes, each driven by mutations in distinct biological pathways.
Researchers from Mayo Clinic have quantified the numbers of various immune cells associated with the risk of developing breast cancer. The study found that women who later developed breast cancer showed lower amounts of antibody-producing immune cells in their breast tissue.
Researchers from New York University Rory Meyers College of Nursing studied genetic and susceptibility risk factors for lymphedema in breast cancer survivors. They found significant associations between genotypes related to several lymphatic and inflammatory genes and symptom phenotypes of impaired limb mobility, fluid accumulation, an...
A national study from England reveals that older women are often excluded from immediate breast reconstruction after mastectomy. Clinicians should adopt standardized assessment tools to identify suitable patients for reconstructive surgery, the findings suggest.
A study of over 2,500 women with newly diagnosed breast cancer revealed a significant gap between the need for genetic testing and its availability. High-risk patients, particularly those from Asian backgrounds and older women, were under-tested due to lack of physician recommendation and inadequate assessment of patient risk and desire.
A recent study published in the journal Cancer found that breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast. The researchers identified 680 stage I, II and III breast cancer patients who were treated at MD Anderson between 1997 and 2012.
A study found that many high-risk breast cancer patients are not recommended for genetic testing, despite being interested in it. The lack of testing puts doctors at risk of missing opportunities to prevent cancers in mutation carriers and their family members.
A new method called synthetic essentiality has been found to identify therapeutic targets in cancers lacking specific key tumor suppressor genes. By analyzing gene deletion patterns, researchers identified CHD1 as a potential treatment site for prostate and breast cancers with PTEN gene loss.
Researchers at Arizona State University have developed a new diagnostic method for detecting pancreatic cancer early in its development by identifying extracellular vesicles with the surface protein EphA2. This technique shows promise for rapid and sensitive detection of various diseases based on unique EV signatures.
A nationwide registry of over 1 million patients with hormone-sensitive breast cancer reveals that 1 in 6 women missed post-surgical adjuvant endocrine therapy, which can lower cancer recurrence risk by 29%. Despite improvements, 18% of eligible women remained untreated between 2004 and 2013
Researchers found that long-term soy consumption improves tamoxifen's effectiveness and reduces breast cancer recurrence. However, starting soy intake after diagnosis increases the risk of cancer recurrence.
A blood test detecting hypermethylation in tumor DNA predicts shorter survival for women with high levels of cancer-linked DNA, indicating worsening disease. The test, cMethDNA, may help identify breast cancers at higher risk for recurrence and track treatment success.
Researchers at Mayo Clinic are testing a vaccine that aims to establish lifelong immunity against precancerous breast lesions. The vaccine targets human epidermal growth factor 2 (HER-2) and has shown promise in a phase I clinical study, eliciting an immune response in all tested individuals.
Scientists have created a 'map' linking cell shape to genes turned on and off, matching it to real disease outcomes. The map revealed key areas controlling gene activity, including a protein called NF-kappaB that drives cancer cell growth and spread.
A new study has found that defects in the EMSY gene, similar to BRCA genes, spur cancer growth independently of BRCA1 and BRCA2 protection. The research suggests new treatment options for women with normal BRCA genes who develop breast and ovarian cancer.
Researchers found that Ewing sarcoma tumors display unique DNA methylation patterns, which influence gene activity and can lead to different outcomes. The study's results provide insights into the biology of Ewing sarcoma and may lead to personalized therapies with fewer side effects.
A study found that inhibiting CCR4 in a mouse model of renal cell carcinoma reduced tumor proliferation and changed the composition of immune cells. The results suggest anti-CCR4 antibodies as a potential therapeutic for multiple cancers linked to abnormal CCR4 expression.
A large study found that breast conserving therapy (BCT) is superior to mastectomy in early-stage breast cancer patients with no metastases. BCT, combined with radiation therapy, offers a survival advantage for patients aged over 50 years and those with comorbidity.
Researchers found that women with ductal carcinoma in situ (DCIS) are at a slightly lower risk of dying from any cause compared to the general population. After 10 years, DCIS patients had a 2.5% risk of dying from breast cancer and a 10% lower overall mortality rate.
Researchers at Huntsman Cancer Institute identified a protein called Macrophage Stimulating Protein (MSP) that causes bone destruction in metastatic breast cancer. A new drug, Ron inhibitor, blocks the activity of MSP, showing promising results in early clinical trials.
Cancer mortality in the US declined by 20.1% from 240 to 192 deaths per 100,000 population between 1980 and 2014. Distinct clusters of counties with high cancer mortality rates were found, varying by type of cancer and region.
Researchers have identified a link between chronic low-level inflammation and increased breast density, raising the risk of breast cancer. By targeting this underlying factor, new approaches to treating breast density and preventing breast cancer may become available.
The study found that the BRCA1 gene is required for the survival of blood forming stem cells, which could explain why patients with BRCA1 mutations do not have an elevated risk for leukemia. The researchers also suggest that these patients may have a tougher time with chemotherapy side effects.
Researchers at the University of Missouri have discovered that luteolin, a natural compound found in herbs and vegetables, can inhibit the growth of triple-negative breast cancer cells in mice. The study found that luteolin reduced metastasis risk by preventing cancer cell migration and viability.
A study found that nearly half of women treated for early stage breast cancer experienced at least one severe or very severe side effect from their treatment. The most common side effects were pain, skin irritation, and constipation, with Latina women being 30% more likely to report a severe side effect.
Researchers found 33 places in breast cancer genomes where tandem duplications were most often found, leading to further cancerous changes. These 'hotspots' may create new driver mutations, making tumours more aggressive and potentially responsive to different treatments.
Researchers found that breast cancer tumors evolve to produce their own estrogen supply, making treatments like aromatase inhibitors ineffective. The study, published in Nature Genetics, aims to increase treatment options for patients whose cancer has returned and spread.
Researchers at UNC have engineered platelets to carry cancer-fighting antibodies, allowing them to target and kill microtumors before they can grow or spread. This innovative approach has shown promising results in animal studies, potentially offering a new hope for patients with recurring cancer after surgery.
Research found that successful immunotherapy activates peripheral 'memory' immune cells, key to long-term defense against cancer. A system-wide immune response is crucial for broadening immunotherapy's effectiveness.
Researchers found that African-American breast cancer patients who receive chemotherapy prior to surgery exhibit reduced regional and distant tumor recurrence rates. Early-stage patients with African-American ancestry display higher tumor recurrence rates compared to European-Americans.
A study by Stanford researchers found that a systemic, whole-body immune response is essential for effectively attacking and eradicating tumors. The researchers used mass cytometry to monitor the physical attributes of individual cells in samples of millions or billions, revealing an increase in immune cells and regulatory T cells in s...
A study published in Health Affairs found that the Affordable Care Act resulted in an 8% increase in early-stage colorectal cancer diagnoses among U.S. seniors aged 65 and older, but had no distinguishable effect on breast cancer diagnoses over the same time period.
Massachusetts General Hospital investigators identified a protein called G3BP2 that helps maintain aggressive tumor-initiating cells in breast cancer. Compounds like C108 can reduce the survival of these cells and slow tumor growth.
Scientists at Huntsman Cancer Institute discovered distinct types of tumors within small cell lung cancer that respond differently to treatment. A targeted drug combination showed improved outcomes for one specific tumor type, suggesting a need for genetic testing and personalized therapies.
Research has discovered a new biological target for reducing tumour spread in cancer patients. The Spns2 gene was found to be involved in regulating the spread of cancers, with targeting it leading to a three-quarters reduction in tumour spread.
A Phase 1 clinical trial found that tucatinib significantly improved outcomes in heavily pretreated patients with HER2+ breast cancer. The drug demonstrated stable disease at 24 weeks or more in 27% of patients, showcasing its potential as a game-changing treatment option.
Researchers from UGR and hospitals Virgen de las Nieves and San Cecilio found that telerehabilitation reduces side effects of breast cancer treatment, such as pain and fatigue. The online exercise program showed excellent results for patients, maintaining benefits even after 6 months.
Researchers at Mayo Clinic have identified a key drug target, CDK4/6, which regulates the spread of triple-negative breast cancer. The study found that inhibiting this protein with CDK 4/6 inhibitors can prevent the metastasis of triple-negative breast cancer to distant organs.
A Danish cohort study found that breast cancer screening was not associated with a reduction in advanced tumors, but rather an increase in nonadvanced tumors and ductal carcinoma in situ (DCIS). The study estimates that approximately 1 in 3 invasive tumors diagnosed in screened women represent overdiagnosis.
Researchers identified LATS as a key player in breast cancer development and treatment. The enzyme's absence leads to increased luminal precursor cells, which can give rise to tumors, and stabilized proteins YAP and TAZ that boost cell proliferation.
A new mouse model has revealed the role of CCN6 protein in developing metaplastic breast cancer, a rare and aggressive subtype of triple-negative breast cancer. The study identified potential genes to target with therapeutics, offering hope for better treatment options for patients.
Researchers have identified a gene mutation driving the formation of metaplastic breast cancer, a subtype of triple negative breast cancer. A therapeutic compound has been validated to slow tumor growth and increase chemotherapy efficacy.
A study published in JNCI Journal of the National Cancer Institute found that high consumption of grilled, barbecued, and smoked meats may increase mortality risk after breast cancer diagnosis. The research evaluated the link between these meat types and survival time among 1508 Long Island women with breast cancer.
A new HER2-targeted dendritic cell vaccine has shown promising results in a clinical trial, stimulating an immune response in 80% of patients and inducing regression of early-stage breast tumors. The vaccine was well-tolerated and effective in both invasive and non-invasive disease settings.
A large study found that 45% more women with breast cancer experience cognitive impairment compared to healthy individuals. Factors like anxiety, younger age, and black race contribute to cognitive decline.
Researchers at Scripps Florida Institute developed a novel approach for identifying how chemicals in the environment can produce infertility and promote breast cancer. The new method uses high-resolution imaging techniques to visualize the effects of estrogenic chemicals on cells.
Molecular imaging techniques have the potential to revolutionize cancer diagnosis, monitoring, and treatment by providing non-invasive alternatives to traditional biopsies. By identifying specific biomarkers, these methods can help doctors choose the most effective treatments, minimize side effects, and predict patient outcomes.
A new study reveals that women with advanced kidney disease are at a higher risk of developing cancer, highlighting the importance of targeted screening strategies.
A new study reveals that inhibiting AXL signaling increases anti-tumor immune response, sensitizes tumors to radiation, and enhances efficacy of anticancer therapies. Aravive-S6 acts as a decoy receptor, binding Gas-6 to prevent AXL activation.
A study analyzing 740 early-stage NSCLC patients treated with SBRT found that Squamous Cell Carcinoma (SqCC) has a significantly higher rate of local failure compared to other histological subtypes. SqCCs are more resistant to SBRT, which may require treatment optimization based on histological subtype.
A new study found that nearly half of early-stage breast cancer patients considered having a double mastectomy, despite knowing it offers little benefit. Patients were unaware of the surgery's risks and benefits, with many choosing it for peace of mind.
A study found that surgeons' recommendations play a crucial role in determining the rate of contralateral prophylactic mastectomy (CPM) in breast cancer patients. Among patients without clinical indications, CPM use was substantial when patients did not receive a recommendation against it, but low when they did.
Researchers at IRB Barcelona have discovered 10 new drug combinations that show high synergy in treating breast cancer, outperforming individual treatments. These combinations aim to overcome treatment resistance by attacking tumour cells from multiple angles.
A new breast cancer model developed by Kaiser Permanente researcher Matthew P. Banegas accurately predicts breast cancer risk in Hispanic patients based on data from Hispanic women. The model, added to the National Cancer Institute's online tool, corrects underestimation of breast cancer risk in Hispanic women.